Showing 2 posts of 2 posts found.


Jyseleca secures European approval in rheumatoid arthritis

September 28, 2020
Research and Development, Sales and Marketing Europe, Jyseleca, arthritis, pharma

The European Commission has awarded approval to Gilead and Galpagos for their oral JAK inhibitor Jyseleca (filgotinib) as a treatment …


Japan approves Gilead and Eisai’s Jyseleca for rheumatoid arthritis

September 25, 2020
Medical Communications, Sales and Marketing Eisai, Gilead, Japan, Jyseleca

Gilead and Eisai have secured approval for their oral JAK1 preferential inhibitor Jyseleca (filgotinib) from the Japanese Ministry of Health, …

Latest content